D
Ligand Pharmaceuticals Incorporated LGND
$102.45 -$2.47-2.35% NASDAQ
Recommendation
Prev Close
$104.92
Volume
84,622
Avg Vol (90D)
111,926
Market Cap
$2.02B
Dividend & Yield
--
52-Week Range
$77.43 - $129.90
P/E (TTM)
--
EPS (TTM)
-$7.12
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Ligand Pharmaceuticals (LGND, $102.45) entered Downtrend as Momentum indicator drops below 0 level on May 21, 2025
5/22/2025 - Tickeron - Stocks
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Recommendation of "Buy" by Analysts
5/21/2025 - Ticker Report
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Buy" by Brokerages
5/18/2025 - MarketBeat
CEO & Director of Ligand Pharmaceuticals Todd Davis Buys 9.2% More Shares
5/16/2025 - Simply Wall St
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) CFO Acquires $156,090.00 in Stock
5/16/2025 - Ticker Report
Deutsche Bank AG Purchases 15,160 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
5/16/2025 - MarketBeat
SPDR S&P Pharmaceuticals ETF -- Insider Buying Index Registering 10.8%
5/15/2025 - ETF Channel
Janus Henderson Group PLC Acquires 5,929 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
5/15/2025 - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Cut to Sell at StockNews.com
5/15/2025 - Ticker Report
Ligand Pharmaceuticals (NASDAQ:LGND) Downgraded to Sell Rating by StockNews.com
5/15/2025 - MarketBeat
Ligand Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
5/14/2025 - Simply Wall St
Ligand to Ring the Nasdaq Opening Bell on May 19, 2025
5/14/2025 - Globe Newswire
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) CEO Todd C. Davis Buys 9,510 Shares
5/14/2025 - MarketBeat
Baird Financial Group Inc. Boosts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
5/11/2025 - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2025 Earnings Guidance
5/10/2025 - MarketBeat
Ligand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...
5/9/2025 - GuruFocus
Q1 2025 Ligand Pharmaceuticals Inc Earnings Call Transcript
5/9/2025 - GuruFocus
Ligand Pharmaceuticals sees 22% CAGR in royalty revenue through 2029
5/8/2025 - SeekingAlpha.com: All News
Ligand Pharmaceuticals Incorporated 2025 Q1 - Results - Earnings Call Presentation
5/8/2025 - SeekingAlpha
Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call Transcript
5/8/2025 - SeekingAlpha
Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call Transcript
5/8/2025 - Seeking Alpha: Transcripts
Ligand Pharmaceuticals Reports Q1 Revenue of $45.3M, Beating Estimates; EPS Falls Short with $2. ...
5/8/2025 - GuruFocus
Ligand Pharmaceuticals Reiterates FY25 Outlook - Update
5/8/2025 - RTT News - Earnings
Ligand Pharmaceuticals GAAP EPS of -$2.21, revenue of $45.3M
5/8/2025 - SeekingAlpha.com: All News
Ligand Reports First Quarter 2025 Financial Results
5/8/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
$181.49M
EBITDA (TTM)
$18.16M
EBIT (TTM)
-$16.63M
Net Income (TTM)
-$132.62M
Balance Sheet
Total Assets (Q)
$905.44M
Total Debt (Q)
$4.45M
Total Liabilities (Q)
$109.90M
Book Value Per Share (Q)
$41.27
Cash Flow
Cash from Operations (TTM)
$52.87M
Cash from Investing (TTM)
-$135.00M
Cash from Financing (TTM)
$80.21M
Net Change in Cash (TTM)
-$2.10M
Filings
Filing Date
Friday, May 9, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 4 and 8 (est)
Price History
Loading...
Beta
1.23
7-Day Total Return
-3.69%
30-Day Total Return
5.98%
60-Day Total Return
-13.69%
90-Day Total Return
-3.60%
Year to Date Total Return
-5.51%
1-Year Total Return
17.76%
2-Year Total Return
35.98%
3-Year Total Return
90.11%
5-Year Total Return
49.81%
52-week Low
Jun 10, 2024 - $77.43
52-week High
Nov 07, 2024 - $129.90
Valuation
Market Cap
$2.02B - Mid Cap
Enterprise Value
$1.82B
Price/Sales (TTM)
11.09
Price/Book (Q)
2.54
Dividends and Shares
Shares Outstanding
19.19M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.ligand.com
Phone Number
858 550 7500
Address
555 Heritage Drive
Jupiter, FL 33458
Country
United States
Year Founded
1987
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL... more
NASDAQ 05/21/2025 4:00PM Eastern Quotes delayed